Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Recruiting · NCT06258642 · Registry updated 2025-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Not applicable | 2025-08-20 | NCT06258642 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer hospital Fudan University | Shanghai | China | 2 |